title: A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.
abstract: These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. The Joint Task Force on Practice Parameters understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because the cost of a given test or agent is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In some instances the cost benefit of an intervention is considered relevant, and commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The Joint Task Force is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the Workgroup convened to draft the parameter, the Task Force Reviewers, and peer review by members of each sponsoring society. Although the Task Force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the Joint Task Force and the Practice Parameters Workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Workgroup chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias.
authors.affiliation: Joint Council of Allergy, Asthma&Immunology, 50 N BrockwaySt, #304, Palatine, IL 60067, USA.
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Zuraw
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Bernstein
authors.forename: David M
authors.initials: DM
authors.lastname: Lang
authors.forename: Timothy
authors.initials: T
authors.lastname: Craig
authors.forename: David
authors.initials: D
authors.lastname: Dreyfus
authors.forename: Fred
authors.initials: F
authors.lastname: Hsieh
authors.forename: David
authors.initials: D
authors.lastname: Khan
authors.forename: Javed
authors.initials: J
authors.lastname: Sheikh
authors.forename: David
authors.initials: D
authors.lastname: Weldon
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
authors.forename: Joann
authors.initials: J
authors.lastname: Blessing-Moore
authors.forename: Linda
authors.initials: L
authors.lastname: Cox
authors.forename: Richard A
authors.initials: RA
authors.lastname: Nicklas
authors.forename: John
authors.initials: J
authors.lastname: Oppenheimer
authors.forename: Jay M
authors.initials: JM
authors.lastname: Portnoy
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Randolph
authors.forename: Diane E
authors.initials: DE
authors.lastname: Schuller
authors.forename: Sheldon L
authors.initials: SL
authors.lastname: Spector
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Tilles
authors.forename: Dana
authors.initials: D
authors.lastname: Wallace
mesh_terms: D000799:Angioedema / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000378:metabolism; D056829:Hereditary Angioedema Types I and II / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D006801:Humans
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors